The Concorde trial compared immediate (Imm) with over follow-up in these markers significantly improved the fit. Markers were also incorporated deferred (Def ) AZT monotherapy in asymptomatic HIV-positive participants. Haematological and into the definition of 'clinical' endpoints. Hazard ratio estimates from end-points that included CD4 immunological markers and weight were measured throughout, and correlated with clinical endpoints.
Introduction
The use of surrogate markers in clinical trials to counts to predetermined levels or to a fixed proportion of baseline values have been used as surrogate assess therapies for a wide range of diseases is controversial.1 In HIV infection it has become a endpoints for disease progression with the aim of increasing the power of clinical trials and enabling major issue because of the increasing difficulty in undertaking trials based on clinical endpoints, partrials to provide answers more quickly. 5 Although viral load, as measured by HIV RNA in ticularly because of the long duration of trials required. Zidovudine (AZT), the most intensively the plasma or serum, has been shown to be an excellent prognostic marker, analysis of cohort studstudied anti-HIV drug to date, has been shown to reduce progression of HIV disease in the short term. 2 ies and the relatively small number of trials which have measured both CD4 and HIV RNA (the latter The clinical effect of AZT has been correlated with effects on a number of laboratory measurements, 3 usually in a subset of participants) have demonstrated that CD4 count is an independent prognostic marker some of which are prognostic markers for disease progression and survival.4 Short-term changes in which may be of particular value at high RNA levels. Data from these trials of nucleoside analogue markers have been used as indicators of changes in disease activity; in particular, effects on CD4 cell reverse transcriptase (RT) inhibitors have been used to explore the role of CD4 and RNA as surrogate count and viral load have been used to evaluate new drugs in phase I and II trials. Decreases of CD4 endpoints, and the results to date indicate that neither marker is adequate.6 Both CD4 and viral load are, baseline value for any individual marker were excluded from all analyses using this marker. An analysis was however, important markers both for predicting progression and assessing response to therapy in the undertaken of the number of participants with results for each of the markers at fixed times after randomizindividual patient, and for assessing new drugs.
It is becoming increasingly difficult to undertake ation to assess the comparability of the two treatment groups. The treatment groups were then compared trials with clinical endpoints, because of the tendency to start antiretroviral therapy earlier in the course of with respect to individual changes from baseline at each 12-weekly follow-up assessment (using the mean the infection and the better management of opportunistic infections and tumours so that larger and longer of all values in an interval of 6 weeks either side of the date), formally testing the global difference between trials are necessary. Further, it is increasingly difficult to maintain compliance with allocated therapy if the groups in marker trajectories. 8 Marker values were Boxcox-transformed for the global test and for there is evidence of disease progression prior to the development of AIDS based on laboratory markers.
estimation of the duration of difference (minimum duration) between the two groups. 8 The latter is defined The increasing number of new drugs and therefore potential combinations means that it is not feasible as the last assessment time at which the marker change differed significantly ( p<0.05) at that and all prior to test all of them in clinical endpoint trials. This has led to regulatory agencies licensing new drugs assessment times, allowing for multiple testing. The early changes in CD4 cell count (at 12 weeks, the first on the basis of their effects on viral load and CD4 cell counts, but with labelling restricted to these immunological assessment of the protocol) were explored in more detail, considering both absolute effects and not to clinical benefit. Longer-term trials will still be essential to assess fully the clinical risks change from baseline and change expressed as a percentage of the baseline value, with and without and benefits of therapies which may be used for several years. stratification for baseline CD4 (100-199, 200-349, 350-499, 500-649 and 650 cells or more). For p24 Concorde was a double-blind placebo-controlled randomized trial in asymptomatic HIV-infected indiantigen, the proportion positive or negative at each assessment was tabulated by treatment group, separviduals (at all levels of CD4 cell count) comparing the effects of a policy of initiating AZT therapy ately for those positive and negative at baseline, and the proportions were compared using a x2 test. For immediately (the Imm group) with a policy of deferring AZT until the participant developed signs of those participants positive at baseline, changes in log 10 p24 antigen (increased by 1 pg/ml to allow for any disease progression (the Def group). The main clinical outcomes during the blinded phase of the trial, over negative results) were compared. The above analyses were performed on an intention-to-treat basis. Some a median follow-up of 3.3 years, have been reported,7 and follow-up continues. The Concorde of the analyses were repeated, censoring each participant's follow-up at the time they stopped trial capsules trial offers the opportunity to describe the clinical effects of AZT and to correlate these with laboratory (AZT or placebo). In addition, for CD4 count, the Imm group was compared with the subgroup (48%) of the changes. This paper reports in detail the effect of AZT on haemoglobin, total white cells, total lymphoDef group who started AZT (on an open-label basis either for symptoms of HIV or low CD4 counts), from cytes, CD4+ lymphocytes (CD4 cells), CD4 percentage, CD4/CD8 ratio, CD8+ lymphocytes (CD8 the time of start of AZT (a non-randomized comparison), using the last CD4 count before AZT as the cells), CD8 percentage, CD3+ lymphocytes (CD3 cells), CD3 percentage, neutrophils, monocytes, baseline and adjusting for this CD4 count. To explore the relationship between the markers platelets, p24 antigen, b2 microglobulin (b2m) and weight. Short-term changes in CD4 counts and b2m and clinical events, the baseline values for each marker were tested univariately in a Cox proportional were analysed to determine whether such changes could have been used to predict treatment effects.
hazards model.9 Backwards elimination and forwards selection (criteria for exit p>0.01 and for entry Attempts were made to develop surrogate endpoints using CD4 counts and b2m levels from the Concorde p<0.01) were then used on the 16 baseline variables to identify a subset of prognostic markers for further data, which could be used in future trials.
evaluation. To investigate whether extra prognostic information could be gained by considering early change in CD4 count (at 12 weeks) as well as the Methods baseline CD4 count, both variables were included as predictors of clinical outcome after 12 weeks in Details of the methods of measuring p24 antigen and b2m in the serum are given in the main report of the a multivariate Cox model. Finally, proportional hazards models with serial CD4 counts and b2m trial.7 Baseline values were calculated as the mean of all pretreatment measurements taken within the 3 levels as time-dependent covariates were used to assess their effect on the instantaneous hazard of months before randomization. Participants without a progression either to ARC, AIDS or death, or to AIDS various haematological markers were between 95% and 96% at 12 weeks, and 83% and 85% at 144 or death.
Hazard ratios (Imm to Def) were calculated for weeks, except for monocytes (94% and 64% at 12 and 144 weeks, respectively); for p24 antigen and different combinations of CD4 and clinical endpoints, with follow up censored at 1, 1. Description of markers at the time of starting AZT. The CD4 changes after the start of AZT were significantly different in the Table 1 HIV-related symptoms, (ii) low CD4 count with HIVrelated symptoms or progression to ARC or AIDS (579 Imm, 567 Def) had results for at least one of the markers considered: after this, the numbers (whether or not confirmed). The Def subgroup with symptoms showed a faster decline in CD4 counts declined rapidly. The proportion with results for individual markers (out of participants known to be compared with both the Def subgroup without symptoms and the Imm group (global p=0.0001 for both alive at each time point and with a baseline) were similar in each treatment group. For both Imm and comparisons). There was marginal evidence of a global difference in the CD4 changes between the Def groups combined, the proportions with results for the various immunological markers were between Def subgroup without symptoms and the Imm group (global p=0.05). Similar results were observed for 86% and 88% at 12 weeks and 73% and 80% at 144 weeks, except for b2m (82% and 48% at 12 change in CD4 count expressed as a percentage of the baseline. and 144 weeks respectively); the proportions for the in median change in CD4/CD8 between the two
Other immunological markers
groups (approximately 4%) persisted for at least 120 The changes in CD4/CD8 ratio show a similar pattern weeks. A similar pattern was observed for the to the CD4 count and CD4 percentage,7 with marked changes in b2m, with an advantage to the Imm differences between the Imm and Def groups (global group persisting for at least 120 weeks (Figure 3 ; p<0.0001). At 12 weeks, there was a median global p<0.0001). increase from baseline of 2.4% in the CD4/CD8
A small but consistent difference between the Imm ratio in the Imm group compared with a decrease of and Def groups was also found in the median 1.8% in the Def group (95% CI for the difference in medians 3.2% to 5.4%; p<0.0001). This difference changes in CD3 percentage (global p=0.002) with higher CD3 percentages in the Imm group (difference Def group than in the Imm group at all weeks after randomization except 156 ( Figure 5 ), although the p in median change (Imm-Def) +1% at weeks 12-48, and 132-156, +1.5% at weeks 96 and 108, and value for a global difference did not reach conventional statistical significance ( p=0.09). For particip-+2% at weeks 60-84 and 120).
No significant difference was found between the ants who were p24 antigen positive at baseline, a significant difference between Imm and Def in the treatment groups in the changes from baseline for CD3 count, CD8 count, CD8 percentage and total median changes in log 10 p24 antigen was seen up to week 48, with an initial decrease in the Imm lymphocyte count (Table 1) . group ( Figure 6 , global p<0.0001).
Effect of starting AZT in the Def group on the Haematological markers CD4 and CD8 comparisons
In the Imm group there was a significant reduction The possible effect on the CD4 and CD8 count of in haemoglobin, white cells, and neutrophils (Tables individuals in the Def group starting AZT was investi-1 and 3). The Imm group showed, on average, a gated, by censoring follow-up when a participant greater decrease from baseline in haemoglobin, total stopped trial capsules ('on-treatment analysis'). As white cells and neutrophils, up to at least week 84, expected, the decline in CD4 from baseline was week 48, and week 84, respectively. In contrast, the slower in both treatment groups after censoring, Imm group had, on average, an initial rise in platelets; because participants with disease progression in both differences between the groups were maintained for groups were more likely to stop trial capsules up to at least week 96 (Tables 1 and 3) . No significant (Figure 4 ). The differences between the groups were difference between the treatment groups was found comparable with those in the intention-to-treat anafor changes in the monocyte count (Table 1) . lysis. For CD8 counts (Table 2) , in the intention-totreat analysis there was a trend to an increase over Weight time in both groups with no significant difference between them. After censoring, the increase in both
In both groups there was, on average, a small groups was greater, but there was still no significant increase in weight at 12 weeks. Median weight difference between the groups. remained above baseline in the Def group, but in the Imm group weight dropped to baseline at 24 p24 antigenaemia weeks, and was below baseline from 72 weeks ( Figure 7 ). The Imm group had a significantly larger A higher proportion of participants who were p24 antigen negative at baseline were positive in the weight loss compared to the Def group from week CD4/CD8 ratio, b2m, p24 antigen, CD8 percentage endpoints (AIDS or death, or ARC, AIDS or death) the 'best' multivariate model included baseline CD4, and total white cell count. Including treatment group as a covariate did not significantly improve the fit.
b2m and p24 antigen (dichotomized as positive or negative). A lower risk of progression to AIDS or Stepwise Cox regression with backwards elimination and forwards selection on the complete set of death was associated with higher baseline CD4 (HR, hazard ratio=0.87 for each +50 cell difference, baseline variables suggested that for both clinical Standard errors for the difference in medians are given in brackets and are calculated using median regression. Numbers with results at various weeks for white cell count, neutrophils and platelets are similar to those given for haemoglobin. 95% CI 0.84-0.91; p<0.0001), lower baseline b2m AIDS or death was associated with higher baseline (HR=1.54 for each +1 mg/l difference, 95% CI CD4 (HR=0.82 for each +50 cell difference, 95% 1.35 to 1.76; p<0.0001), and negative p24 anti-CI 0.79-0.85; p<0.0001), and greater increase in genaemia at baseline (HR=2.10 positive:negative, CD4 at 12 weeks (HR=0.91 for each 50 cell 95% CI 1.58-2.78; p<0.0001). Applying these increase from baseline, 95% CI 0.87-0.96; p= hazard ratios to the observed differences at 12 weeks 0.0002). There was no evidence that the effect of between Imm and Def in CD4 count and b2m level baseline CD4 or change in CD4 at 12 weeks differed and the proportion p24 positive would predict a between the treatment groups, and including treatrelative reduction for progression to AIDS or death ment group as a covariate did not improve the fit of of 21% in Imm compared with Def (95% CI 11-30% the model significantly. When models relating basereduction), compared with an observed increase of line b2m and change in b2m to progression to AIDS 1% (95% CI 18% reduction to 24% increase). HR or death were used, a lower risk of progression to estimates for progression to ARC, AIDS or death AIDS or death was associated with lower baseline (based on the baseline values) were similar, and b2m (HR=2.16 for each +1 mg/l difference in would predict a 20% relative reduction for progresbaseline, 95% CI 1.90-2.45; p<0.0001) and sion to ARC, AIDS or death in Imm compared with smaller increase at 12 weeks (HR=1.44 for each Def if applied in the same way to the differences 1 mg/l increase at 12 weeks, 95% CI 1.20-1.73; seen at 12 weeks, compared with an observed p<0.0001); there was no evidence that the effect of reduction of 11%.
b2m differed with treatment group. (Similar results were obtained for progression to ARC, AIDS or death
Serial marker values using both models.) When both CD4 and b2m The relationship between serial CD4 counts and (baseline and change at 12 weeks) were included in b2m levels and clinical progression was investigated the model, all four variables were highly significant further (p24 antigen was not included, as less than and there was no evidence of any interactions with 16% of all values were positive). the treatment group. Hazard ratio estimates were similar to those from the models above, with a Effect of early changes in CD4 and b2m. To assess slightly smaller effect of the baselines. On the basis whether the change from baseline to 12 weeks added of the observed changes in CD4 and b2m at 12 to the prognostic value of CD4 at baseline, a weeks in the two groups (assuming equal baselines), multivariate proportional hazards model relating both we would predict, using this final model, a relative the change and the baseline to progression to AIDS or death was used. A lower risk of progression to reduction for progression to ARC, AIDS or death of 14% in Imm compared with Def, and a 15% relative Treatment effect on CD4 counts and reduction for AIDS or death.
clinical endpoints
Clinical endpoints
Changes in markers throughout follow-up. Serial CD4 counts and b2m levels were used as timeThere appeared to be a consistent but not statistically dependent covariates in proportional hazards significant survival advantage in the Def group, when models, with the most recent marker value used to follow-up was censored at 1, 1.5, 2, 3 and 4 years, update the hazard at each time. A higher instantanalthough there were small numbers of events at the eous risk of progression to ARC, AIDS or death was early time points (Table 4 ). Progression to AIDS or associated with lower CD4 (HR=1.30 for each death showed a non-significant advantage to the 50-cell decrease in CD4, 95% CI 1.26-1.33;
Imm group, censoring follow-up at 1 year only. p<0.0001), and higher b2m (HR=1.42 for each There appeared to be a consistent benefit in progres-1 mg/l higher b2m, 95% CI 1. 33-1.52; p<0.0001) .
sion to ARC, AIDS or death to the Imm group, which There was evidence that the effect of CD4 was was statistically significant when follow-up was significantly different in the two treatment groups censored at 1 and 1.5 years after randomization, (x2=10.06, df=1, p=0.002). The risk ratio for each but not subsequently. Hazard ratios obtained from 50-cell decrease in CD4 was 1.25 in the Def group censoring follow-up at 1.5 and 3 years were between (95% CI 1.21-1.30) and 1.35 in the Imm group the hazard ratios obtained censoring at 1 and 2 (95% CI 1.30-1.40). Thus, the same rate of CD4 years, and 2 and 4 years, respectively. decline in the two groups would be associated with a higher rate of progression to ARC, AIDS or death
CD4 endpoints and combined clinical and CD4
in Imm than in Def. There was no evidence for a endpoints different effect of b2m in the two groups (x2=1.11, df=1, p=0.29). For progression to AIDS or death,
The hazard ratios (Imm5Def ) for progression to any of the CD4 endpoints were similar if based on one similar hazard ratio estimates were obtained for the overall effect of serial CD4 and b2m; there was no count or on two consecutive counts (whether combined with clinical endpoints or not), and therefore evidence that the effect of CD4 was different in the two groups (x2=0.62, df=1, p=0.42) but there the results presented are for one count only. For each of the CD4 endpoints, the hazard ratio for was marginal evidence (x2=4.00, df=1, p=0.05) of an increased risk of progression in Imm compared progression to the CD4 endpoint alone was similar to the hazard ratio for progression to the CD4 with Def after adjustment for serial CD4 and b2m. Including baseline CD4 and b2m (for which there endpoint or AIDS or death, and the hazard ratios for progression to the combined CD4 endpoint, AIDS or was marginal evidence that they were independent predictors of clinical outcome) in the model did not death are therefore presented. Three patterns were observed in the hazard ratios change the other hazard ratio estimates appreciably.
Finally, the association between the serial counts over the five censoring time-points (Table 4) . First, hazard ratios for the combined endpoint of AIDS or of all 16 markers and clinical progression was investigated using forward selection (entry level p death or either (i) CD4 <200, or (ii) drop below 75% or (iii) drop below 50% of baseline CD4 level value=0.01). A higher risk of progressing to AIDS or death was associated with lower CD4 (HR=1.36 showed a significant advantage to the Imm group when follow-up was censored at 1, 1.5, 2, 3 and 4 for each 50 cell lower CD4, 95% CI 1.30-1.42; p<0.0001), higher b2m (HR=1.34 for each 1 mg/l years. Secondly, hazard ratios for progression to AIDS or death or either (i) CD4 <100, or (ii) CD4 higher b2m, 95% CI 1.23-1.46; p<0.0001), lower haemoglobin (HR=1.41 for each 1g/dl lower hae-<50, or (iii) drop to 25% of baseline CD4 showed a non-significant advantage to the Imm group at moglobin, 95% CI 1.33-1.50; p<0.0001) and higher white cell count (HR=1.05 for each 109/l increase every censoring time. Thirdly, no significant differences between the two groups were observed at any in white cells, 95% CI 1.02-1.09, p=0.002); and in this model there was no evidence that the effect censoring time in the hazard ratios for progression to AIDS or death or CD4 <25, with hazard ratios of any of these markers differed between treatment groups, nor was there a significant additional treatclose to one at every censoring time except 1 year. The hazard ratios and number of events for ment effect (Imm: Def HR=1.15, p=0.19) . Similar results were obtained for progression to ARC, AIDS progression to CD4 endpoints or AIDS or death are shown in Figure 8 , censoring follow-up at 2 and 4 or death, but the model now included neutrophil rather than white cell count, and also CD4 peryears after randomization, to assess whether the CD4 endpoints add to the clinical endpoints. At four centage and p24 antigen status. Serial weight measurements were not independently prognostic years, the hazard ratio estimate for CD4 <25 is closest to that for AIDS or death, but adds very little in either model. The first line shows the number of events, the second line the hazard ratio, with 95% CIs in brackets. The 23 participants with no baseline CD4 count are not included. * Total events up to 31 December 1992. information, as there are very few extra events. At effect moves away from the hazard ratio for progression to AIDS or death at 4 years. The hazard ratios two years, the hazard ratio estimates for CD4 <50 and CD4 <25 are closest to that for AIDS or death, for progression to CD4 <50, CD4 <25 and drop to 25% of baseline CD4 censoring at 2 years agree but again there is little difference between these three endpoints in the number of events.
most closely with the hazard ratio for AIDS or death censoring both at 2 and 4 years. In addition, an assessment of the ability of the combined CD4 and AIDS or death endpoints with
The addition of b2m to marker endpoints defined by CD4 did not show an advantage over either the follow-up censored at 2 years to predict the hazard ratio for progression to AIDS or death censored at combined AIDS or death or CD4 endpoint, or the AIDS or death endpoint, for any of the various com-4 years was undertaken ( Figure 9 ). As both types of CD4 endpoints become less extreme, the number of binations considered. Accuracy was not improved by combination with an extreme b2m endpoint (75% events increases, but the estimate of the treatment Figure 9 . Hazard ratios for CD4 endpoints at 2 years compared with hazard ratios for progression to AIDS or death at 2 and 4 years. or 100% gain from baseline) (which resulted in a asymptomatic individuals in the Imm group, the increased CD4 cell turnover would dominate, reduction in the number of events), and accuracy was lost by combination with a less extreme b2m whereas in the Def subgroup who started open AZT at least in part because of symptoms, the CD4 rise endpoint (25% or 50% gain from baseline) (which resulted in an increase in the number of events). might be depressed. The Concorde data confirm those from previous Combined haemoglobin, b2m and CD4 endpoints were not considered, as there were very few participstudies3,4,10 that CD4, b2 microglobulin and p24 antigen at baseline are major independent prognostic ants (8.5% of the Imm group and 2.1% of the Def group) who had even a relatively mild reduction in factors for HIV disease progression. However, the prognostic effect of changes in these markers subhaemoglobin (below 10 g/dl).
sequent to randomization was different between the Imm and Def groups. Assuming 12-week values predict clinical progression in the same way as
Discussion baseline values, the hazard ratio (Imm5Def) for progression to AIDS or death predicted from the This paper describes changes in markers of HIV infection in response to AZT therapy and correlates mean observed CD4, b2m and p24 at 12 weeks was 0.77, which is lower than the observed hazard ratio them with clinical endpoints in a placebo-controlled trial comparing two policies of AZT therapy. The of 1.01 (95% CI 0.82-1.24). The change in CD4 counts and b2m levels from baseline to 12 weeks results confirm that AZT increases CD4 cells and the CD4/CD8 ratio, and decreases serum b2m and p24 acted as additional independent prognostic factors to the baseline values, and the hazard ratio antigen levels. The expected decrease in haemoglobin and neutrophil counts was also observed, (Imm5Def ) for progression to AIDS or death predicted by the mean observed change in CD4 and together with a modest increase in platelet count. Immediate treatment with AZT was associated with, b2m at 12 weeks was 0.85. Association between serial marker values and clinical progression showed on average, a small loss in weight which became apparent in the second year of the study. The effect that (i) considering markers of activity only, for any CD4 count the hazard of progression was increased of AZT on different markers highlights the difficulty of distinguishing between markers which measure by immediate AZT therapy, and (ii) considering all markers, the hazard of progression was increased by disease activity or progression, and those which indicate possible toxic effects of the drug. low CD4, high b2m and low haemoglobin. The effect of AZT on immunological parameters comThe early CD4 cell count response to AZT has been described in detail in order to allow comparison bined with its effect on haematological parameters may partly explain why the CD4 rise with AZT did with newer anti-HIV drugs. For participants with baseline CD4 counts between 100 and 500, the not translate into clinical benefit. The Concorde data have been extensively median CD4 count change at 12 weeks in the Imm group was 41 cells per ml (95% CI 25-57) greater explored to determine whether a CD4-dependent endpoint could be devised which would have prothan the change in the Def group, and was independent of baseline CD4 count. In contrast, the effect of vided a valid result more quickly or with a smaller number of participants, and could therefore be used AZT in participants with higher CD4 counts was much smaller and indeed in participants with nearin future trials. Concorde used three different clinical endpoint definitions, which gave somewhat different normal CD4 counts, AZT appeared to have no effect. These results imply that the relative effect of AZT on results. Progression to AIDS or death was used as the reference clinical result because of potential CD4 counts decreases with increasing baseline CD4 counts. The Concorde trial also allowed a nonproblems in establishing a rigorous definition of ARC (which might make this endpoint unreliable) and randomized comparison between the CD4 response in Def participants who started open AZT therapy because there were relatively small numbers of deaths. A number of different CD4-defined endpoints either for symptoms of HIV or for low CD4 counts alone. Participants in the Def subgroup who started were used, censoring at several times from randomization. Any combined clinical and CD4 endpoint AZT because of symptoms, rather than a falling CD4 count alone, appeared to have a poorer CD4 which increased the power of the study, also biased the results away from the reference result in the response compared to Imm participants with comparable baseline CD4 counts. The reason for the differdirection of benefit to immediate treatment. Use of the more stringent endpoints (CD4 <25 or 50) did ences in the CD4 changes is unclear. It is tempting to speculate that the size of the CD4 rise is propornot bias the results, but the additional CD4 endpoints did not occur sufficiently frequently in participants tional to the size of the CD4 cell turnover which in turn increases as the number of CD4 cells falls, but without clinical endpoints to add to the power of the study. In general, the CD4 endpoints agreed might decrease with advanced HIV disease. In more closely with the ARC, AIDS or death endpoint:
investigate the role of these markers as surrogate markers to determine the clinical efficacy of new but none of the CD4-dependent endpoints showed close agreement with mortality. Attempts to incorportreatments. Prentice21 has suggested that for a surrogate marker ate changes in b2 microglobulin failed to provide closer agreement with clinical endpoints (either by to be valid, 'a test of the null hypothesis of no relationship (of the marker) to the treatment group improving power or decreasing bias). It is possible that some of the discrepancy between markermust also be a valid test of the corresponding null hypothesis based on the true endpoint'. Thus changes dependent endpoints and clinical endpoints can be explained by the development of viral resistance to over time must correlate with the risk of progression, and any effect of treatment on the risk of clinical AZT and some can also be explained by clinically undetected toxicity. Short-term changes in markers, progression must be explainable and predictable by the effect of treatment on the markers. To date this CD4 or viral load, may not adequately predict longterm clinical benefit, because subsequent failures of has not been demonstrated for CD4 cell counts or any other laboratory marker, although as yet relatherapy may be related to the development of viral resistance; which may be unrelated to the limited tively few data have been available on viral load. However even if the Prentice criteria are satisfied for responses.
Data from several other trials have been used to a marker, information on the size of the effect is also required to make clinical decisions to weigh attempt to assess the surrogacy of CD4 cell counts and more recently, viral load. However in some the the benefits against the risks of toxicity. Such a quantitative relationship is difficult to predict. use of short-term or incomplete results has complicated the interpretation. An analysis of the results of This report describes the effect of AZT on surrogate markers and explores their potential role in clinical a similar trial to Concorde, ACTG 019,11 conducted in the US, explored the proportion of the effect of trials. Attempts to incorporate markers into the definition of clinical endpoints in order to increase the AZT on disease progression explained by the effect on CD4 cell count. As in Concorde, the current CD4 power and shorten the duration of clinical trial proved disappointing. The correlation between AZTcount was significantly correlated with progression to AIDS but only a portion of the effect of AZT on induced short-term improvements in prognostic markers and long-term clinical effects was also progression was explained by its effect on the CD4 count.12 However, the average follow-up in ACTG disappointing. It is possible that CD4 is simply an invalid marker of treatment effect, but it is also 019 was only just over 1 year, and Concorde demonstrated that the early benefit was not mainpossible that more effective treatments will produce much greater changes in CD4 counts which would tained over a longer period of follow-up. More recently an analysis of viral load from stored specitranslate into clinical benefit.22 The Concorde trial was completed before the more recent quantitative mens from a second similar US study (VA 29813) was reported to indicate that changes in viral load virological assays were available. However, preliminary analyses of the additional virological studies correlated with a delay in disease progression in the groups which received immediate therapy. However, within the Delta trial and several other trials confirm the value of RNA as a prognostic marker, but do not in this trial there were several deaths before AIDS, and if these are included in a combined endpoint of indicate that it will provide more useful predictors of treatment activity than CD4 counts.6 Further AIDS or death, there is in fact no significant difference between the immediate and deferred groups in spite analyses to attempt to validate surrogate markers against the results from long-term clinical trials are of the persistent differences in both CD4 and viral load.14 Viral load was not measured in Concorde, essential, to assess whether they can be used as a method of evaluating the clinical benefit of new and there are no plans to undertake the assays retrospectively. The serum samples were not stored treatment regimens in trials beyond Phase II. under ideal conditions and are now nearly 10 years old. There are now a number of studies of combination therapies which demonstrate a substantial and
